ID   YES_HUMAN               Reviewed;         543 AA.
AC   P07947; A6NLB3; D3DUH1;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=Tyrosine-protein kinase Yes;
DE            EC=2.7.10.2;
DE   AltName: Full=Proto-oncogene c-Yes;
DE   AltName: Full=p61-Yes;
GN   Name=YES1; Synonyms=YES;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2436037; DOI=10.1128/MCB.7.1.41;
RA   Sukegawa J., Semba K., Yamanashi Y., Nishizawa M., Miyajima N.,
RA   Yamamoto T., Toyoshima K.;
RT   "Characterization of cDNA clones for the human c-yes gene.";
RL   Mol. Cell. Biol. 7:41-47(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D.,
RA   Taylor T.D., Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Yang X., Abouelleil A., Allen N.R., Anderson S.,
RA   Bloom T., Bugalter B., Butler J., Cook A., DeCaprio D., Engels R.,
RA   Garber M., Gnirke A., Hafez N., Hall J.L., Norman C.H., Itoh T.,
RA   Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., Macdonald P., Mauceli E.,
RA   Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., Noguchi H.,
RA   O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=2021534; DOI=10.1038/bjc.1991.121;
RA   Sugawara K., Sugawara I., Sukegawa J., Akatsuka T., Yamamoto T.,
RA   Morita M., Mori S., Toyoshima K.;
RT   "Distribution of c-yes-1 gene product in various cells and tissues.";
RL   Br. J. Cancer 63:508-513(1991).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=2067846;
RA   Krueger J., Zhao Y.H., Murphy D., Sudol M.;
RT   "Differential expression of p62c-yes in normal, hyperplastic and
RT   neoplastic human epidermis.";
RL   Oncogene 6:933-940(1991).
RN   [7]
RP   PALMITOYLATION.
RX   PubMed=7980442; DOI=10.1042/bj3030749;
RA   Koegl M., Zlatkine P., Ley S.C., Courtneidge S.A., Magee A.I.;
RT   "Palmitoylation of multiple Src-family kinases at a homologous N-
RT   terminal motif.";
RL   Biochem. J. 303:749-753(1994).
RN   [8]
RP   PHOSPHORYLATION BY CSK.
RX   PubMed=9281320; DOI=10.1006/abbi.1997.0236;
RA   Sun G., Budde R.J.;
RT   "Expression, purification, and initial characterization of human Yes
RT   protein tyrosine kinase from a bacterial expression system.";
RL   Arch. Biochem. Biophys. 345:135-142(1997).
RN   [9]
RP   PHOSPHORYLATION AT TYR-426, AND MUTAGENESIS OF TYR-426.
RX   PubMed=9794236; DOI=10.1038/sj.onc.1202076;
RA   Sun G., Sharma A.K., Budde R.J.;
RT   "Autophosphorylation of Src and Yes blocks their inactivation by Csk
RT   phosphorylation.";
RL   Oncogene 17:1587-1595(1998).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=11901164; DOI=10.1083/jcb.200109005;
RA   Lee S.W., Bonnah R.A., Higashi D.L., Atkinson J.P., Milgram S.L.,
RA   So M.;
RT   "CD46 is phosphorylated at tyrosine 354 upon infection of epithelial
RT   cells by Neisseria gonorrhoeae.";
RL   J. Cell Biol. 156:951-957(2002).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=16338789; DOI=10.1080/08977190500199360;
RA   Clump D.A., Qazi I.H., Sudol M., Flynn D.C.;
RT   "c-Yes response to growth factor activation.";
RL   Growth Factors 23:263-272(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF CDK4.
RX   PubMed=18479465; DOI=10.1111/j.1742-4658.2008.06463.x;
RA   Martin N.G., McAndrew P.C., Eve P.D., Garrett M.D.;
RT   "Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is
RT   mediated by Src family kinases.";
RL   FEBS J. 275:3099-3109(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-537, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-21 AND SER-40, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF DPYSL2.
RX   PubMed=19276087; DOI=10.1074/jbc.M807664200;
RA   Varrin-Doyer M., Vincent P., Cavagna S., Auvergnon N., Noraz N.,
RA   Rogemond V., Honnorat J., Moradi-Ameli M., Giraudon P.;
RT   "Phosphorylation of collapsin response mediator protein 2 on Tyr-479
RT   regulates CXCL12-induced T lymphocyte migration.";
RL   J. Biol. Chem. 284:13265-13276(2009).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19258394; DOI=10.1242/jcs.034843;
RA   Sato I., Obata Y., Kasahara K., Nakayama Y., Fukumoto Y., Yamasaki T.,
RA   Yokoyama K.K., Saito T., Yamaguchi N.;
RT   "Differential trafficking of Src, Lyn, Yes and Fyn is specified by the
RT   state of palmitoylation in the SH4 domain.";
RL   J. Cell Sci. 122:965-975(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-336; TYR-345 AND
RP   TYR-537, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21566460; DOI=10.4161/cc.10.9.15495;
RA   Jung J., Lee M.K., Jin Y., Fu S.B., Rosales J.L., Lee K.Y.;
RT   "Clues for c-Yes involvement in the cell cycle and cytokinesis.";
RL   Cell Cycle 10:1502-1503(2011).
RN   [20]
RP   FUNCTION.
RX   PubMed=21713032; DOI=10.1371/journal.pbio.1001090;
RA   Tauzin S., Chaigne-Delalande B., Selva E., Khadra N., Daburon S.,
RA   Contin-Bordes C., Blanco P., Le Seyec J., Ducret T., Counillon L.,
RA   Moreau J.F., Hofman P., Vacher P., Legembre P.;
RT   "The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven
RT   cell migration pathway.";
RL   PLoS Biol. 9:E1001090-E1001090(2011).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 91-152.
RX   PubMed=17418139; DOI=10.1016/j.febslet.2007.03.059;
RA   Martin-Garcia J.M., Luque I., Mateo P.L., Ruiz-Sanz J.,
RA   Camara-Artigas A.;
RT   "Crystallographic structure of the SH3 domain of the human c-Yes
RT   tyrosine kinase: loop flexibility and amyloid aggregation.";
RL   FEBS Lett. 581:1701-1706(2007).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-198 AND ARG-282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein tyrosine kinase that is involved in
CC       the regulation of cell growth and survival, apoptosis, cell-cell
CC       adhesion, cytoskeleton remodeling, and differentiation.
CC       Stimulation by receptor tyrosine kinases (RTKs) including EGRF,
CC       PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the
CC       phosphorylated receptor, and activation and phosphorylation of
CC       downstream substrates. Upon EGFR activation, promotes the
CC       phosphorylation of PARD3 to favor epithelial tight junction
CC       assembly. Participates in the phosphorylation of specific
CC       junctional components such as CTNND1 by stimulating the FYN and
CC       FER tyrosine kinases at cell-cell contacts. Upon T-cell
CC       stimulation by CXCL12, phosphorylates collapsin response mediator
CC       protein 2/DPYSL2 and induces T-cell migration. Participates in
CC       CD95L/FASLG signaling pathway and mediates AKT-mediated cell
CC       migration. Plays a role in cell cycle progression by
CC       phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating
CC       the G1 phase. Also involved in G2/M progression and cytokinesis.
CC       {ECO:0000269|PubMed:11901164, ECO:0000269|PubMed:18479465,
CC       ECO:0000269|PubMed:19276087, ECO:0000269|PubMed:21566460,
CC       ECO:0000269|PubMed:21713032}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Interacts with YAP1 and CSF1R (By similarity). Interacts
CC       with CTNND1; this interaction allows YES1-mediated activation of
CC       FYN and FER and subsequent phosphorylation of CTNND1 (By
CC       similarity). Interacts with FASLG. {ECO:0000250,
CC       ECO:0000269|PubMed:19807924}.
CC   -!- INTERACTION:
CC       P09917:ALOX5; NbExp=2; IntAct=EBI-515331, EBI-79934;
CC       P10275:AR; NbExp=5; IntAct=EBI-515331, EBI-608057;
CC       Q6P1W5:C1orf94; NbExp=3; IntAct=EBI-515331, EBI-946029;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-515331, EBI-297353;
CC       Q8IVP5:FUNDC1; NbExp=3; IntAct=EBI-515331, EBI-3059266;
CC       P51116:FXR2; NbExp=3; IntAct=EBI-515331, EBI-740459;
CC       Q13480:GAB1; NbExp=7; IntAct=EBI-515331, EBI-517684;
CC       P10721:KIT; NbExp=7; IntAct=EBI-515331, EBI-1379503;
CC       Q9H204:MED28; NbExp=2; IntAct=EBI-515331, EBI-514199;
CC       P08581:MET; NbExp=3; IntAct=EBI-515331, EBI-1039152;
CC       Q9GZT8:NIF3L1; NbExp=3; IntAct=EBI-515331, EBI-740897;
CC       Q8TAK6:OLIG1; NbExp=3; IntAct=EBI-515331, EBI-3867416;
CC       I6L996:PTK2; NbExp=3; IntAct=EBI-515331, EBI-10181089;
CC       O14543:SOCS3; NbExp=3; IntAct=EBI-515331, EBI-714146;
CC       Q9BWW4:SSBP3; NbExp=3; IntAct=EBI-515331, EBI-2902395;
CC       Q9NVV9:THAP1; NbExp=3; IntAct=EBI-515331, EBI-741515;
CC       Q12933:TRAF2; NbExp=3; IntAct=EBI-515331, EBI-355744;
CC       Q9Y4K3:TRAF6; NbExp=3; IntAct=EBI-515331, EBI-359276;
CC       Q96BR9:ZBTB8A; NbExp=3; IntAct=EBI-515331, EBI-742740;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Cytoplasm, cytosol.
CC       Note=Newly synthesized protein initially accumulates in the Golgi
CC       region and traffics to the plasma membrane through the exocytic
CC       pathway.
CC   -!- TISSUE SPECIFICITY: Expressed in the epithelial cells of renal
CC       proximal tubules and stomach as well as hematopoietic cells in the
CC       bone marrow and spleen in the fetal tissues. In adult, expressed
CC       in epithelial cells of the renal proximal tubules and present in
CC       keratinocytes in the basal epidermal layer of epidermis.
CC       {ECO:0000269|PubMed:2021534, ECO:0000269|PubMed:2067846}.
CC   -!- PTM: Phosphorylation by CSK on the C-terminal tail maintains the
CC       enzyme in an inactive state. Autophosphorylation at Tyr-426
CC       maintains enzyme activity by blocking CSK-mediated inhibition.
CC       {ECO:0000269|PubMed:11901164, ECO:0000269|PubMed:9281320,
CC       ECO:0000269|PubMed:9794236}.
CC   -!- PTM: Palmitoylation at Cys-3 promotes membrane localization.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15990; AAA35735.1; -; mRNA.
DR   EMBL; AP001178; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471113; EAX01709.1; -; Genomic_DNA.
DR   EMBL; CH471113; EAX01710.1; -; Genomic_DNA.
DR   EMBL; BC048960; AAH48960.1; -; mRNA.
DR   CCDS; CCDS11824.1; -.
DR   PIR; A26714; TVHUYS.
DR   RefSeq; NP_005424.1; NM_005433.3.
DR   RefSeq; XP_016881449.1; XM_017025960.1.
DR   UniGene; Hs.194148; -.
DR   PDB; 2HDA; X-ray; 1.90 A; A=91-152.
DR   PDBsum; 2HDA; -.
DR   ProteinModelPortal; P07947; -.
DR   SMR; P07947; -.
DR   BioGrid; 113357; 118.
DR   DIP; DIP-33849N; -.
DR   IntAct; P07947; 52.
DR   MINT; MINT-93566; -.
DR   STRING; 9606.ENSP00000324740; -.
DR   BindingDB; P07947; -.
DR   ChEMBL; CHEMBL2073; -.
DR   DrugBank; DB01254; Dasatinib.
DR   GuidetoPHARMACOLOGY; 2284; -.
DR   iPTMnet; P07947; -.
DR   PhosphoSitePlus; P07947; -.
DR   SwissPalm; P07947; -.
DR   BioMuta; YES1; -.
DR   DMDM; 125870; -.
DR   EPD; P07947; -.
DR   MaxQB; P07947; -.
DR   PaxDb; P07947; -.
DR   PeptideAtlas; P07947; -.
DR   PRIDE; P07947; -.
DR   DNASU; 7525; -.
DR   Ensembl; ENST00000314574; ENSP00000324740; ENSG00000176105.
DR   Ensembl; ENST00000584307; ENSP00000462468; ENSG00000176105.
DR   GeneID; 7525; -.
DR   KEGG; hsa:7525; -.
DR   UCSC; uc002kky.4; human.
DR   CTD; 7525; -.
DR   DisGeNET; 7525; -.
DR   GeneCards; YES1; -.
DR   HGNC; HGNC:12841; YES1.
DR   HPA; CAB004370; -.
DR   HPA; HPA026480; -.
DR   MIM; 164880; gene.
DR   neXtProt; NX_P07947; -.
DR   OpenTargets; ENSG00000176105; -.
DR   PharmGKB; PA37432; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P07947; -.
DR   KO; K05705; -.
DR   PhylomeDB; P07947; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   SignaLink; P07947; -.
DR   SIGNOR; P07947; -.
DR   ChiTaRS; YES1; human.
DR   EvolutionaryTrace; P07947; -.
DR   GeneWiki; YES1; -.
DR   GenomeRNAi; 7525; -.
DR   PRO; PR:P07947; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000176105; -.
DR   CleanEx; HS_YES1; -.
DR   ExpressionAtlas; P07947; baseline and differential.
DR   Genevisible; P07947; HS.
DR   GO; GO:0005884; C:actin filament; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:BHF-UCL.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0015758; P:glucose transport; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0043114; P:regulation of vascular permeability; TAS:BHF-UCL.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Complete proteome;
KW   Cytoplasm; Cytoskeleton; Kinase; Lipoprotein; Membrane; Myristate;
KW   Nucleotide-binding; Palmitate; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    543       Tyrosine-protein kinase Yes.
FT                                /FTId=PRO_0000088181.
FT   DOMAIN       91    152       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      158    255       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      277    530       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     283    291       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    396    396       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     305    305       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      21     21       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES      32     32       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q04736}.
FT   MOD_RES      40     40       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     336    336       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     345    345       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     426    426       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9794236}.
FT   MOD_RES     446    446       Phosphotyrosine. {ECO:0000305}.
FT   MOD_RES     537    537       Phosphotyrosine; by CSK.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   LIPID         2      2       N-myristoyl glycine. {ECO:0000250}.
FT   LIPID         3      3       S-palmitoyl cysteine; in membrane form.
FT                                {ECO:0000250}.
FT   VARIANT     198    198       I -> V (in dbSNP:rs34580680).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041879.
FT   VARIANT     282    282       K -> R (in dbSNP:rs35126906).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041880.
FT   MUTAGEN     426    426       Y->F: About 50% loss of CSK-mediated
FT                                inhibition. {ECO:0000269|PubMed:9794236}.
FT   STRAND       93    100       {ECO:0000244|PDB:2HDA}.
FT   STRAND      117    121       {ECO:0000244|PDB:2HDA}.
FT   STRAND      126    133       {ECO:0000244|PDB:2HDA}.
FT   TURN        134    136       {ECO:0000244|PDB:2HDA}.
FT   STRAND      139    143       {ECO:0000244|PDB:2HDA}.
FT   HELIX       144    146       {ECO:0000244|PDB:2HDA}.
FT   STRAND      147    149       {ECO:0000244|PDB:2HDA}.
SQ   SEQUENCE   543 AA;  60801 MW;  A2B376084686BBCD CRC64;
     MGCIKSKENK SPAIKYRPEN TPEPVSTSVS HYGAEPTTVS PCPSSSAKGT AVNFSSLSMT
     PFGGSSGVTP FGGASSSFSV VPSSYPAGLT GGVTIFVALY DYEARTTEDL SFKKGERFQI
     INNTEGDWWE ARSIATGKNG YIPSNYVAPA DSIQAEEWYF GKMGRKDAER LLLNPGNQRG
     IFLVRESETT KGAYSLSIRD WDEIRGDNVK HYKIRKLDNG GYYITTRAQF DTLQKLVKHY
     TEHADGLCHK LTTVCPTVKP QTQGLAKDAW EIPRESLRLE VKLGQGCFGE VWMGTWNGTT
     KVAIKTLKPG TMMPEAFLQE AQIMKKLRHD KLVPLYAVVS EEPIYIVTEF MSKGSLLDFL
     KEGDGKYLKL PQLVDMAAQI ADGMAYIERM NYIHRDLRAA NILVGENLVC KIADFGLARL
     IEDNEYTARQ GAKFPIKWTA PEAALYGRFT IKSDVWSFGI LQTELVTKGR VPYPGMVNRE
     VLEQVERGYR MPCPQGCPES LHELMNLCWK KDPDERPTFE YIQSFLEDYF TATEPQYQPG
     ENL
//
